Opportunity Information: Apply for PA 12 161
Apply for PA 12 161
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Basic Research on HIV Persistence (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242 Mental Health Research Grants 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research 93.396 Cancer Biology Research 93.399 Cancer Control 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Jul 18, 2014 and posted on Apr 12, 2012.
- Applicants must submit their applications by Jul 19, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Small businesses Native American tribal governments (Federally recognized) State governments Private institutions of higher education Independent school districts Public and State controlled institutions of higher education County governments Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Native American tribal organizations (other than Federally recognized tribal governments) Public housing authorities/Indian housing authorities.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity Basic Research on HIV Persistence (R01), identified as PA-12-161, is a discretionary grant program that uses the Research Project Grant (R01) mechanism to support hypothesis-driven basic research aimed at explaining why HIV-1 can persist in people even when they are receiving highly active antiretroviral therapy (HAART). The central goal is to deepen scientific understanding of the biological and mechanistic basis of persistent infection and residual virus in treated individuals, with an emphasis on foundational work that can unlock new paths toward either long-term remission without continuous treatment (sometimes described as a functional cure) or, ultimately, complete eradication of remaining virus (a sterilizing cure). The announcement highlights innovation as a priority, encouraging investigators to introduce new concepts, experimental strategies, and technical approaches that can clarify how HIV-1 reservoirs are established, maintained, and measured under suppressive therapy.
A key feature of this FOA is its focus on research that directly advances the field of HIV persistence, including the creation or improvement of experimental models and laboratory assays. Model development can include systems that more accurately mimic the cellular and tissue environments where HIV persists, while assay development can include methods that better quantify or characterize residual virus, latent infection, or reservoir dynamics. The reason these tools are emphasized is practical: better models and measurements are often the bottleneck for progress, and advancements here are expected to feed into later-stage translational and clinical studies that test therapeutic strategies. In other words, this FOA is positioned as upstream, basic science support that lays the groundwork for future interventions designed to achieve durable remission off therapy or complete cure.
Administratively, the opportunity is offered by the National Institutes of Health and falls under multiple health-related and biomedical research assistance listings (CFDA/assistance numbers) that include mental health research grants, several cancer-related research categories, and allergy, immunology, microbiology, and infectious disease research (for example, 93.855 and 93.856). This broad mapping reflects how HIV persistence intersects with immunology, virology, oncology-related biology (such as cellular proliferation and persistence), and other disease mechanisms. The FOA does not require cost sharing or matching, which means applicants are not required to contribute non-federal funds as a condition of receiving the award.
Eligibility is expansive and includes a wide range of organization types across the public, private, nonprofit, and educational sectors. Eligible applicants include public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations with or without 501(c)(3) status, for-profit organizations (including small businesses), and many government entities such as state, county, city or township governments, special district governments, independent school districts, and tribal governments and organizations (including those not federally recognized). The FOA also explicitly includes various mission- and community-focused institutions and organizations, such as historically Black colleges and universities (HBCUs), Hispanic-serving institutions, tribally controlled colleges and universities (TCCUs), Alaska Native and Native Hawaiian-serving institutions, faith-based or community-based organizations, and U.S. territories or possessions. Importantly, non-U.S. entities (foreign institutions) are eligible to apply, and foreign components of U.S. organizations are allowed as defined by NIH policy, signaling NIH interest in globally relevant scientific contributions to HIV cure-related research.
In terms of timing and status, the FOA was posted on April 12, 2012, with an original closing date listed as January 7, 2015. The record provided also includes dates indicating updates and archival status (creation date July 18, 2014; current closing date July 19, 2014; archive date August 19, 2014), which suggests the specific listing has since closed and been archived, even though the original closing date field appears elsewhere in the record. Applicants looking for current opportunities in this topic area would typically use the archived announcement as a reference point and then search NIH for the most recent HIV persistence or HIV cure-related FOAs that continue this line of funding.
For access and support, the full announcement is available through the NIH Grants Guide at the provided link (http://grants.nih.gov/grants/guide/pa-files/PA-12-161.html). The contact information included is primarily technical support for accessing or linking to the announcement, routed through the NIH Office of Extramural Research (OER) webmaster emails.
FAQs: NIH Basic Research on HIV Persistence (R01) - PA-12-161
What is the funding opportunity called?
The opportunity is titled Basic Research on HIV Persistence (R01) and is identified as PA-12-161.
Which agency is offering this grant?
This is a National Institutes of Health (NIH) funding opportunity.
What type of grant mechanism does this opportunity use?
The announcement uses the Research Project Grant (R01) mechanism.
What is the overall purpose of this FOA?
The FOA supports hypothesis-driven basic research focused on understanding why HIV-1 can persist in people who are receiving highly active antiretroviral therapy (HAART).
What is the central scientific goal of the program?
The central goal is to deepen scientific understanding of the biological and mechanistic basis of persistent infection and residual virus in treated individuals, with the aim of enabling future progress toward long-term remission without continuous treatment (functional cure) or complete eradication (sterilizing cure).
Is this opportunity focused on basic science or clinical trials?
Based on the description provided, the FOA is positioned as upstream, basic science support intended to lay groundwork for later-stage translational and clinical studies.
What research themes does the FOA emphasize?
The FOA emphasizes foundational research that clarifies how HIV-1 reservoirs are established, maintained, and measured under suppressive therapy.
How important is innovation in this FOA?
Innovation is highlighted as a priority. Investigators are encouraged to bring new concepts, experimental strategies, and technical approaches that advance understanding of HIV persistence and reservoirs.
Does the FOA support development of experimental models?
Yes. A key feature is support for the creation or improvement of experimental models, including systems that better mimic the cellular and tissue environments where HIV persists.
Does the FOA support development or improvement of assays?
Yes. The FOA emphasizes assay development, including methods to better quantify or characterize residual virus, latent infection, or reservoir dynamics.
Why does the FOA place special emphasis on models and assays?
The announcement notes that improved models and measurements are often a bottleneck for progress. Advancements in these tools are expected to feed into later-stage studies that evaluate therapeutic strategies aimed at durable remission or cure.
What is meant by "residual virus" and "HIV persistence" in the context of this FOA?
In this FOA, these terms refer to HIV-1 that remains in treated individuals despite suppressive therapy, including persistent infection and reservoirs that are difficult to detect and eliminate using current approaches.
Does the FOA require cost sharing or matching funds?
No. The FOA states that cost sharing/matching is not required, meaning applicants do not have to provide non-federal funds as a condition of award.
What CFDA/assistance listings are associated with this opportunity?
The FOA is mapped to multiple NIH assistance listings that include areas such as mental health research, cancer-related research categories, and allergy, immunology, microbiology, and infectious disease research, with examples including 93.855 and 93.856.
Why is the FOA mapped across multiple health and biomedical research categories?
The broad mapping reflects that HIV persistence intersects with multiple fields, including immunology, virology, and biology relevant to oncology-related mechanisms (such as cellular proliferation and persistence), among others.
Who is eligible to apply?
Eligibility is broad and includes many organization types across public, private, nonprofit, educational, and government sectors.
Are higher education institutions eligible?
Yes. Eligible applicants include both public and state-controlled institutions of higher education and private institutions of higher education.
Are nonprofit organizations eligible?
Yes. Nonprofit organizations are eligible, including those with or without 501(c)(3) status.
Are for-profit organizations eligible?
Yes. For-profit organizations, including small businesses, are listed as eligible applicants.
Are government entities eligible?
Yes. Eligible government applicants include state, county, city or township governments, special district governments, independent school districts, and tribal governments and organizations (including those not federally recognized).
Are mission- and community-focused institutions explicitly included?
Yes. The FOA explicitly includes institutions and organizations such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities (TCCUs), Alaska Native and Native Hawaiian-serving institutions, and faith-based or community-based organizations.
Are U.S. territories or possessions eligible?
Yes. The FOA includes eligibility for U.S. territories or possessions.
Are foreign (non-U.S.) institutions eligible to apply?
Yes. The FOA states that non-U.S. entities (foreign institutions) are eligible to apply.
Are foreign components of U.S. organizations allowed?
Yes. Foreign components of U.S. organizations are allowed as defined by NIH policy.
What does the inclusion of foreign applicants and components imply about the program?
It signals NIH interest in globally relevant scientific contributions to HIV persistence and cure-related research.
When was this FOA posted?
The FOA was posted on April 12, 2012.
What are the closing date details provided for this FOA?
The record includes an original closing date listed as January 7, 2015. It also shows other record dates suggesting updates and archival activity (including creation date July 18, 2014, a current closing date July 19, 2014, and an archive date August 19, 2014).
Is this FOA still open?
Based on the dates provided (including an archive date), the specific listing appears to be closed and archived.
If this FOA is archived, how should it be used?
The archived announcement can be used as a reference point for the type of research NIH sought to support, and applicants would typically search NIH for more recent HIV persistence or HIV cure-related FOAs that continue this funding area.
Where can the full announcement be found?
The full announcement is available through the NIH Grants Guide at: http://grants.nih.gov/grants/guide/pa-files/PA-12-161.html
What contact information is provided for access or technical support?
The contact information provided is primarily for technical support related to accessing or linking to the announcement, routed through the NIH Office of Extramural Research (OER) webmaster emails.
Browse more opportunities from the same category: Education Health
Next opportunity: Specialized Centers of Excellence in ELSI Research (CEER) (P50)
Previous opportunity: Basic Research on HIV Persistence (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 12 161
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 12 161) also looked into and applied for these:
| Funding Opportunity |
|---|
| Clinical Sequencing Exploratory Research (U01) Apply for RFA HG 12 009 Funding Number: RFA HG 12 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,500,000 |
| Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (R34) Apply for PA 12 171 Funding Number: PA 12 171 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| Pre Application for the FY13 NIDA Avant Garde Award Program for HIV/AIDS Research (X02) Apply for PAR 12 164 Funding Number: PAR 12 164 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| FY13 NIDA Avant Garde Award Program for HIV/AIDS Research (DP1) Apply for RFA DA 13 002 Funding Number: RFA DA 13 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Identifying Health Outcomes Associated with Changes in Use of Illicit Drugs (R01) Apply for RFA DA 13 007 Funding Number: RFA DA 13 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Synthesis and Preclinical Evaluation of Medications to Treat Substance Use Disorders (SUDs) (R01) Apply for RFA DA 13 004 Funding Number: RFA DA 13 004 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Innovative Health Information Technology for Broad Adoption by Healthcare Systems and Consumers (SBIR) (R44) Apply for PA 12 196 Funding Number: PA 12 196 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Community Clinical Oncology Program Groups (U10) Apply for RFA CA 12 007 Funding Number: RFA CA 12 007 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Minority Based Community Clinical Oncology Program Groups (U10) Apply for RFA CA 12 008 Funding Number: RFA CA 12 008 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NIMH Career Transition Award for Tenure Track and Tenured Intramural Investigators (K22) Apply for PAR 12 201 Funding Number: PAR 12 201 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research Education Grants for Statistical and Computational Training in the Genetics of Addiction (R25) Apply for PAR 12 199 Funding Number: PAR 12 199 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| U.S. India Bilateral Collaborative Research Partnerships (CRP) on the Prevention of HIV/AIDS and Co morbidities (R21) Apply for RFA AI 12 033 Funding Number: RFA AI 12 033 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Establish Sharing of Human Brain Image Data Relevant to Drug Addiction (Admin Supp) Apply for PAR 12 204 Funding Number: PAR 12 204 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Advancing Exceptional Research on HIV/AIDS (R01) Apply for RFA DA 13 008 Funding Number: RFA DA 13 008 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Identifying Non coding RNA Targets for Early Detection of Cancer (R01) Apply for PA 12 213 Funding Number: PA 12 213 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Identifying Non coding RNA Targets for Early Detection of Cancer (R21) Apply for PA 12 214 Funding Number: PA 12 214 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Biomarkers for Early Detection of Hematopoietic Malignancies (R21) Apply for PA 12 220 Funding Number: PA 12 220 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Biomarkers for Early Detection of Hematopoietic Malignancies (R01) Apply for PA 12 221 Funding Number: PA 12 221 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cohort Studies of HIV/AIDS and Substance Use (U01) Apply for PAR 12 222 Funding Number: PAR 12 222 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Community level Approaches to Reduce HIV Infection in Highly Impacted Communities (R01) Apply for RFA MH 13 090 Funding Number: RFA MH 13 090 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 12 161", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.